Inclusion Criteria:  Patients over 18 years old; Patients with left ventricular thrombus newly found by body surface ultrasound less than or equal to 3 months before selection, with no limitation on basic diseases; Patients who received standard anticoagulant therapy for less than 4 weeks before enrollment did not use antiplatelet drugs or only used single antiplatelet drugs; The patients voluntarily joined the study and signed the informed consent.  Exclusion Criteria:  Patients with contraindications to rivaroxaban anticoagulation therapy; Patients with a history of acute pulmonary embolism or deep venous thrombosis within a week need intensive anticoagulant therapy; Patients with history of hemorrhagic stroke within one week; Patients with cardiac benign and malignant tumors; Aspirin and P2Y12 receptor antagonists should be kept; In patients with severe hepatic and renal insufficiency, alanine aminotransferase > 3 times the upper limit and total bilirubin > 2 times the upper limit, creatinine clearance rate < 15ml / min / 1.73m2; The patient's history of intracerebral hemorrhage and active hemorrhage was 8 months; Patients with hematological diseases, hemoglobin < 100g / L, platelet < 80 x 10^9 / L; Women with pregnancy status, planned pregnancy and lactation period; Patients with life expectancy less than 1 year; Patients enrolled in other clinical studies; Other situations considered unsuitable by the researcher. Note: anticoagulant therapy can be given to patients with left ventricular thrombosis combined with hemorrhagic stroke ≥ 4 weeks or recent ischemic stroke / transient ischemic attack according to the specific situation.